Pharmamarketeer

Allergan’s Vraylar wins FDA approval for bipolar depression

Allergan Plc’s Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

Medhc-fases-banner
Advertentie(s)